From 2026 onwards, SpringBoard, the industry association for medical technology, will continue as part of LIFE Cooperative. This is a logical step, as both organizations pursue the same goals for their members. With this integration, the knowledge, experience, and network of SpringBoard will become part of LIFE Cooperative — the cooperative of more than 60 Northern Dutch Life Science companies. This marks an important step toward strengthening and further growing the Life Science & Health sector in the Northern Netherlands.
“We complement each other perfectly and are even stronger together. By joining forces in this way, we increase the effectiveness of the solutions developed to contribute to sustainable healthcare. In doing so, we create economic opportunities for our members!”
— Ronald Hesse, Director of LIFE Cooperative
Since its founding in 2014, LIFE Cooperative has worked closely and enthusiastically with SpringBoard. On behalf of SpringBoard, Jan Thalens has played an important role in this collaboration by contributing to the further development of the cooperative as a member of LIFE Cooperative’s board.
In 2025, SpringBoard decided it was time for the next step. LIFE Cooperative shares this ambition and will further expand its activities in the field of Enabling Technologies & Medical Devices starting in 2026.
“Together, we are creating new opportunities for our members and strengthening the ecosystem around medical technology,” says Jan Thalens, board member of SpringBoard.
LIFE Cooperative promotes innovation in the life sciences by facilitating collaboration between entrepreneurs, researchers, and investors. Through various programs and events, LIFE fosters the development of technologies that improve health and well-being. The cooperative represents more than 60 companies in the Northern Netherlands — from ambitious startups and innovative SMEs to international players. Together, they account for approximately 5,000 FTEs and a turnover of €500 million.
SpringBoard is an independent industry association for medical technology, founded in 2008 as an initiative by former employees of Cordis Roden. The network has grown to about 65 members and promotes innovation and knowledge sharing, supports entrepreneurs, and assists in setting up new companies. SpringBoard has contributed to the creation of seven new companies and around 100 jobs. Through workshops, networking events, and an open innovation platform, SpringBoard strengthens the MedTech sector and the development of human capital in the Northern Netherlands.
In the North, and in Groningen in particular, there are dozens of companies working on innovations in the fields of life sciences and health. There are many hidden gems among them, says Ronald Hesse, director of the LIFE Cooperative partnership. “Millions of patients worldwide have already benefited from innovations developed here in Groningen,” he says.
Researchers at the UMCG and their spin-off CC Diagnostics, located on Campus Groningen, have developed a new test that could make cervical cancer screening more efficient and user-friendly.
A full house, sharp discussions, and an afternoon in which science and industry visibly strengthened one another. The Dutch Medicines Winter Afternoon demonstrated that Groningen is not only a strong geographical spot, but also a substantive force within the Dutch life sciences landscape. The event, organized by FIGON (Federation for Innovative Drug Research Netherlands) in collaboration with LIFE Cooperative, brought professionals from across the Netherlands to the north. Researchers, entrepreneurs, developers, and clinical experts gathered around one shared ambition: to bring innovative medicines to patients faster, smarter, and better.Klaas Poelstra, Chair of FIGON, looks back positively on the event: “It was great to see local businesses in the health sector and leading academic scientists engaging in conversation with one another. They have so much to gain from each other.“From what to how What became particularly clear during the Dutch Medicines Winter Afternoon was how rapidly the field of drug development is evolving, and how essential collaboration has become. At a time when therapies are increasingly targeted, complex, and costly, the focus is shifting from only what we develop to how we do so: more intelligently, more sustainably, and better aligned with patient needs. This broader context was already reflected in the opening remarks by Klaas Poelstra, who emphasized the importance of continued innovation for the Netherlands’ competitive position and patient care. On behalf of the LIFE Cooperative, Robert Hof highlighted that regional collaboration is a decisive factor: by bringing science, entrepreneurship, and clinical practice closer together, real acceleration can be achieved. The first substantive contributions made it clear that innovation today is not only about new molecules, but also about new delivery methods. Rob Steendam demonstrated how long-acting microspheres can improve treatment adherence and reduce patient burden. Jaap Wieling showed how inhalation technology is evolving into a platform for both local and systemic therapies. Through her research on polyelectrolyte coacervates, Marleen Kamperman placed these innovations within a fundamental scientific framework. After the break, the discussion shifted to clinical translation and advanced nanomedicines. Flávia Sousa illustrated how polymer-based nanomedicines contribute to targeted brain delivery. Ad Roffel underscored the importance of robust pharmacokinetic studies in an era where the demands for evidence continue to increase. Erik Frijlink reflected on innovation within both existing and new delivery systems, while Helder Santos outlined the potential of RNA delivery via nanotechnology for cardiac tissue repair.More than a program During the closing networking reception, it became clear what participants had gained from the afternoon. As Robert Hof, Board Member of the LIFE Cooperative, put it: “The FIGON Winter Afternoon was an excellent event with distinguished speakers and strong engagement. We look forward to the next edition and extend our sincere thanks to Klaas Poelstra and FIGON for hosting the event in the Northern Netherlands.” The common thread throughout the afternoon was therefore unmistakable: the future of medicines does not lie within a single discipline, but in the connections between them. In a time of increasing healthcare pressure, rapid technological advancement, and international competition, such collaboration is not a luxury—it is a necessity. The Dutch Medicines Winter Afternoon showed that this collaboration is firmly rooted in the Northern Netherlands and that Groningen is positioning itself emphatically as a breeding ground and accelerator for innovative drug development.
